Literature DB >> 8459744

Middle ear disease in young children with sensorineural hearing loss.

P E Brookhouser1, D W Worthington, W J Kelly.   

Abstract

Early identification of children with sensorineural hearing loss (SNHL), coupled with the provision of appropriate conventional amplification constitute important elements of a (re)habilitative strategy. Often overlooked, however, is the problem posed by recurrent and chronic middle ear disease in the child with coexisting SNHL. This study focuses on 437 (237 boys and 200 girls) consecutive patients with bilateral SNHL, in the moderate range or poorer, who were diagnosed prior to age 5 years at Boys Town National Research Hospital. The mean threshold shift with effusion was 25.0 dB at 250 Hz, 28.5 dB at 500 Hz, 29.5 dB at 1000 Hz, 24.5 dB at 2000 Hz, and 27.5 dB at 4000 Hz. During a median follow-up period of 3.21 years, 154 (35.2%) of these children required surgical placement of tympanostomy tubes because of the severity of middle ear disease and its impact on auditory acuity. Accurate determination of the degree and audiologic configuration of a SNHL may be seriously hindered by a coexisting middle ear effusion. If initial findings indicate the presence of a middle ear effusion, measures of auditory function must be repeated after the effusion has been resolved by medical and/or surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459744     DOI: 10.1002/lary.5541030402

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Auditory functions in children at schools for the deaf.

Authors:  Erkan Karatas; Muzaffer Kanlikama; Semih Mumbuc
Journal:  J Natl Med Assoc       Date:  2006-02       Impact factor: 1.798

2.  Ectopic mineralization in the middle ear and chronic otitis media with effusion caused by RPL38 deficiency in the Tail-short (Ts) mouse.

Authors:  Konrad Noben-Trauth; Joseph R Latoche
Journal:  J Biol Chem       Date:  2010-11-09       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.